MARKET

CGON

CGON

CG Oncology, Inc.
NASDAQ
53.09
+2.01
+3.94%
Pre Market: 53.44 +0.35 +0.66% 07:22 02/11 EST
OPEN
51.37
PREV CLOSE
51.08
HIGH
53.88
LOW
51.23
VOLUME
103
TURNOVER
0
52 WEEK HIGH
57.88
52 WEEK LOW
14.80
MARKET CAP
4.28B
P/E (TTM)
-26.1901
1D
5D
1M
3M
1Y
5Y
1D
CG Oncology price target raised to $75 from $66 at Truist
TipRanks · 22h ago
Expert Outlook: CG Oncology Through The Eyes Of 7 Analysts
Benzinga · 23h ago
CG Oncology Is Maintained at Buy by Truist Securities
Dow Jones · 23h ago
CG Oncology Price Target Raised to $75.00/Share From $66.00 by Truist Securities
Dow Jones · 23h ago
CG Oncology, Inc. (CGON) Gets a Buy from Truist Financial
TipRanks · 1d ago
CG ONCOLOGY INC <CGON.O>: TRUIST SECURITIES RAISES TARGET PRICE TO $75 FROM $66
Reuters · 1d ago
Weekly Report: what happened at CGON last week (0202-0206)?
Weekly Report · 2d ago
Analysts’ Top Healthcare Picks: Cormedix (CRMD), CG Oncology, Inc. (CGON)
TipRanks · 6d ago
More
About CGON
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).

Webull offers CG Oncology Inc stock information, including NASDAQ: CGON real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CGON stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CGON stock methods without spending real money on the virtual paper trading platform.